🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Lübeck
Clinical trial register · Germany

Clinical Trials in Lübeck, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Germany and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5051 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:51 UTC
5051
Studies in scope
all four open statuses
2882
Recruiting now
open to new participants
988
Lead sponsors
across recruiting studies
Top sites
Berlin 1584 Hamburg 889 Essen 760 Dresden 707 Heidelberg 627
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
University Hospital Schleswig-Holstein10 University of Luebeck9 Novartis Pharmaceuticals8 GlaxoSmithKline8 AstraZeneca7
Site location
Berlin1584 Hamburg889 Essen760 Dresden707 Heidelberg627
All 635 locations
Target enrolment
to

Trials with a site in Lübeck

225 of 5051 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Germany
Start
Not yet open
Augmented Reality Aided Remote Access and Technical Support for Complex Ablation Procedures
NCT07777042Atrial Fibrillation (AF)
University of Luebeck
Not applicable
60
Lübeck
2026-08
Recruiting
Evaluation of the Efficacy and Safety of Magnetic Resonance Angiography (MRA) Using Gadopiclenol Compared to Gadoterate Meglumine in the Assessment of Steno-occlusive Disease in Adult Patients With Suspected Vascular Disease
NCT07348640Steno-occlusive Disease
DrugsGadopiclenol·Gadoterate meglumine
Guerbet
Phase 3
315
Berlin, Bonn, Essen, Homburg, Kiel, Lübeck, München
2026-07-28
Recruiting
A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis
NCT07497087Systemic Sclerosis
Boehringer Ingelheim
Phase 3
448
Bad Bramstedt, Berlin, Dresden, Freiburg im Breisgau, Hanover, Heidelberg, Lübeck, Münster
2026-07-27
Recruiting
GRAnulomatous MAstitis REGistry Study
NCT07422870Idiopathic Granulomatous Mastitis, Granulomatous Mastitis
European Breast Cancer Research Association of Surgical Trialists
Observational
1,000
Düsseldorf, Lübeck
2026-07-01
Not yet open
Impact of a Reminder App on Physical Activity During Radiation Therapy for Lung Cancer
NCT07627022Lung Cancer
University Hospital Schleswig-Holstein
Not applicable
32
Hanover, Kiel, Lübeck
2026-07-01
Not yet open
Chemotherapy-Induced Peripheral Neuropathy - Additional Evaluation in Breast Cancer Survivors
NCT07604441Breast Cancer
University Hospital Schleswig-Holstein
Not applicable
28
Lübeck
2026-06-01
Recruiting
MacuTherm Performance Study in Patients With iAMD
NCT07607496Intermediate AMD
OD-OS MacuTherm GmbH
Not applicable
240
Detmold, Hanover, Lübeck, Mannheim, Münster, Potsdam, Schleswig, Trier
2026-05-29
Recruiting
A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis
NCT07599813Atopic Dermatitis, Atopic, Dermatitis, Dermatitis, Atopic
Apollo Therapeutics Ltd
Phase 2
280
Bad Bentheim, Dresden, Frankfurt, Hamburg, Lübeck, Münster, Witten
2026-05-28
Recruiting
A Substudy of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis
NCT07571174Amyotrophic Lateral Sclerosis
DrugLY4256984
Eli Lilly and Company
Phase 1
32
Lübeck, Rostock, Ulm
2026-05-14
Recruiting
A Master Protocol (OLMP): A Study of LY4256984 in Participants With Amyotrophic Lateral Sclerosis (ALS)
NCT07571200Amyotrophic Lateral Sclerosis
DrugLY4256984
Eli Lilly and Company
Phase 1
32
Lübeck, Rostock, Ulm
2026-05-14
Not yet open
Stratification and Treatment in Early Psychosis Study - PROMOTE
NCT07434973Clinical High Risk for Psychosis (CHR), Clinical High Risk for Psychosis, Clinical High Risk for Developing Psychosis
DrugCannabidiol
University of Oxford
Phase 3
586
Berlin, Cologne, Lübeck, München
2026-05-01
Recruiting
A Study of LTX-002 in Adult Participants With Amyotrophic Lateral Sclerosis
NCT07660614Amyotrophic Lateral Sclerosis
Leal Therapeutics, Inc
Phase 1/2
56
Lübeck
2026-04-29
Recruiting
Comprehensive LEFt Atrial Appendage Occlusion With Rhythm Restoration
NCT07523620Atrial Fibrillation (AF), Paroxysmal AF, Persistent Atrial Fibrillation
Abbott Medical Devices
Not applicable
240
Frankfurt am Main, Lübeck, Berlin
2026-03-31
Recruiting
A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
NCT07291076Hepatocellular Carcinoma (HCC)
DrugsPumitamig·Ipilimumab
Bristol-Myers Squibb
Phase 1/2
198
Cologne, Lübeck, Frankfurt, Mainz
2026-03-16
Recruiting
A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
NCT07431177Non-segmental Vitiligo
DrugGIA632
Novartis Pharmaceuticals
Phase 2
210
Munich, Bad Bentheim, Bielefeld, Hamburg, Hanover, Lübeck, Münster, Tübingen
2026-03-09
Recruiting
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
NCT07284849CRC (Colorectal Cancer)
DrugsINCA33890·Folfox·Bevacizumab
Incyte Corporation
Phase 3
700
Berlin, Dresden, Essen, Frankfurt am Main, Freiburg im Breisgau, Hamburg, Hanover, Lübeck
2026-03-05
Recruiting
Efficacy and Safety of Oral Controlled-release Nicotinic Acid (CIR-NA) for the Remission of Prediabetes. (CONCEPT)
NCT07286747Prediabetes (Insulin Resistance, Impaired Glucose Tolerance)
University Hospital Schleswig-Holstein
Phase 2
390
Berlin, Kiel, Leipzig, Lübeck, München, Tübingen
2026-03-03
Recruiting
Neoadjuvant Darovasertib in Primary Uveal Melanoma
NCT07015190Uveal Melanoma
DrugDarovasertib
IDEAYA Biosciences
Phase 3
520
Tübingen, Ulm, Erlangen, Essen, Dessau, Berlin, Bonn, Lübeck
2026-01-25
Recruiting
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT07222566Advanced Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)
DrugsPF-08634404·Pembrolizumab
Pfizer
Phase 3
1,410
München, Frankfurt am Main, Kassel, Georgsmarienhütte, Chemnitz, Halle, Lübeck, Berlin
2026-01-06
Recruiting
A Study to Assess NAV-240 in Adult Participants With Hidradenitis Suppurativa
NCT07384975Hidradenitis Suppurativa (HS)
Navigator Medicines, Inc.
Phase 2
150
Bochum, Frankfurt, Kiel, Lübeck, Mainz
2026-01-05
Recruiting
A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant
NCT06932562Multiple Myeloma
DrugsLinvoseltamab·Daratumumab·Lenalidomide·Dexamethasone
European Myeloma Network B.V.
Phase 3
1,000
Greifswald, Lübeck, Würzburg
2025-12-23
Recruiting
WATCHMAN FLX Pro European Registry
NCT07262255Non-valvular Atrial Fibrillation (AF), Left Atrial Appendage Closure
Boston Scientific Corporation
Observational
1,000
Bad Oeynhausen, Berlin, Erfurt, Hamburg, Lübeck
2025-12-17
Recruiting
SGLT2 Inhibition for Cardiovascular Endpoint Reduction in Hypertension
NCT06804161Atrial Hypertension
Prof. Dr. med. Ingo Eitel
Phase 3
3,000
Lübeck
2025-12-10
Recruiting
A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-1)
NCT07276724Severe Asthma
DrugGB-0895
Generate Biomedicines
Phase 3
786
Deggingen, München, Frankfurt am Main, Witten, Leipzig, Lübeck, Berlin
2025-12-03
Recruiting
PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS
NCT07142291Amyotrophic Lateral Sclerosis (ALS)
DrugsCromolyn Sodium·Riluzole
PhenoNet, Inc.
Phase 2
105
Berlin, Hanover, Lübeck
2025-11-25
Active, closed
A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.
NCT07228390Hidradenitis Suppurativa
DrugRitlecitinib
Pfizer
Phase 2
128
Dresden, Frankfurt, Lübeck
2025-11-13
Recruiting
A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa
NCT07287644Hidradenitis Suppurativa (HS)
DrugBFB759
Bluefin Biomedicine, Inc.
Phase 2/3
210
Bochum, Frankfurt, Heidelberg, Leipzig, Lübeck, Munich
2025-11-03
Recruiting
Study to Collect Real-world Performance and Safety Data on Penumbra System® in Population With Acute Ischemic Stroke (AIS).
NCT07107022Acute Ischemic Stroke (AIS)
Penumbra Inc.
Observational
200
München, Recklinghausen, Augsburg, Lübeck
2025-11-01
Recruiting
Intervention With Tralokinumab in Patients With Moderate-to-severe Atopic Dermatitis With Genital Impact
NCT07444801Atopic Dermatitis (Moderate-to-severe) Involving the Genital Region
DrugTralokinumab
University Hospital Schleswig-Holstein
Observational
30
Augsburg, Lübeck
2025-10-20
Recruiting
A Non-interventional Study of Participants With BPDCN Treated With Chemotherapy
NCT07785180Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Stemline Therapeutics, Inc.
Observational
140
Bremen, Chemnitz, Leipzig, Lübeck, Munich, Oldenburg, Würzburg
2025-10-17
Recruiting
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
NCT07028853Metastatic Castration Sensitive Prostate Cancer (mCSPC), Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate
DrugsMevrometostat·Xtandi·Enzalutamide
Pfizer
Phase 3
1,000
Heidelberg, Nürtingen, Ulm, Mettmann, Lübeck, Berlin, Düsseldorf, Hamburg
2025-09-28
Recruiting
Streamlined Denervation With spYral For an Optimized Treatment (SPYRAL SWYFT) in Subjects With Uncontrolled Hypertension
NCT07115953Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases
Medtronic Vascular
Not applicable
130
Homburg, Lübeck, Erlangen, Leipzig, Villingen-Schwenningen
2025-09-22
Recruiting
Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis
NCT07023835Amyotrophic Lateral Sclerosis (ALS)
Zydus Therapeutics Inc.
Phase 2
240
Dresden, Hanover, Jena, Lübeck, Rostock, Ulm
2025-09-17
Recruiting
A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to Severe Palmoplantar Pustulosis
NCT07013201Palmoplantar Pustulosis
DrugDelgocitinib
LEO Pharma
Phase 2
135
Bad Bentheim, Dresden, Göttingen, Kiel, Lübeck, Manheim, Münster, Osnabrück
2025-09-11
Recruiting
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT06973187Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
DrugsTacabrutideg·Pirtobrutinib
BeOne Medicines
Phase 3
500
Bochum, Bonn, Cologne, Dortmund, Karlsruhe, Lübeck, Stuttgart, Ulm
2025-09-04
Not yet open
Resistance Profiling Using Functional Imaging and Next Generation Sequencing in Refractory Gastrointestinal Stomal Tumors (GIST)
NCT07109024Gastrointestinal Stromal Tumor (GIST)
Universität Duisburg-Essen
Observational
40
Essen, Lübeck
2025-09-01
Recruiting
A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]
NCT07099898Neoplasms, Lung
DrugsRis-Rez·Topotecan
GlaxoSmithKline
Phase 3
420
Karlsruhe, Löwenstein, Augsburg, Chemnitz, Esslingen am Neckar, Heidelberg, Lübeck, München
2025-08-11
By invitation
Transfemoral TAVI With or Without Coronary Angiogram in Patients With Severe Aortic Stenosis (PURE TAVI)
NCT06898086Severe Aortic Stenosis
Rede Optimus Hospitalar SA
Not applicable
620
Düsseldorf, Essen, Freiburg im Breisgau, Lübeck, Ulm
2025-08-08
Recruiting
A Study of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis
NCT07100119ALS (Amyotrophic Lateral Sclerosis)
DrugLY4256984
Eli Lilly and Company
Phase 1
32
Lübeck, Rostock, Ulm
2025-08-05
Active, closed
Study to Evaluate the Safety, Pharmacology and Efficacy of WIN378 in Adults With Moderate or Severe Asthma
NCT07120503Asthma (Diagnosis)
DrugWIN378
Windward Bio
Phase 2
136
Berlin, München, Bendorf, Lübeck, Darmstadt, Frankfurt am Main, Leipzig, Mainz
2025-07-24
Recruiting
ELEVATE-HFpEF Clinical Study
NCT06678841Heart Failure With Preserved Ejection Fraction (HFpEF)
Medtronic Cardiac Rhythm and Heart Failure
Not applicable
700
Lübeck
2025-07-09
Recruiting
Follitropin Delta in Long GnRH-agonist Protocol
NCT06995261Infertility (IVF Patients), Infertility, Infertility Drugs
Prof. Dr. med. M.Sc. Georg Griesinger
Observational
350
Düsseldorf, Saarbrücken, Kiel, Lübeck
2025-07-09
Active, closed
An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
NCT06991556Metastatic Hormone-sensitive Prostate Cancer
DrugsLuxdegalutamide·Abiraterone·Enzalutamide
Novartis Pharmaceuticals
Phase 2
168
Düsseldorf, Hamburg, Lübeck, Nürtingen
2025-07-07
Recruiting
Single-Fraction Very Accelerated Partial Breast Irradiation (sfVAPBI)
NCT07067437Breast Neoplasms
National Institute of Oncology, Hungary
Not applicable
250
Bremerhaven, Erlangen, Lübeck, Offenbach, Würzburg
2025-07-01
Not yet open
Reminder App to Optimize Bladder Filling During Radiotherapy for Prostate Cancer
NCT06653751Prostate Cancer Patients Treated by Radiotherapy
University Hospital Schleswig-Holstein
Not applicable
28
Hanover, Schwerin, Flensburg, Lübeck
2025-07-01
Active, closed
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)
NCT06959225Hidradenitis Suppurativa
DrugRuxolitinib
Incyte Corporation
Phase 3
580
Berlin, Bochum, Darmstadt, Dresden, Erlangen, Hamburg, Lübeck
2025-06-23
Recruiting
A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)
NCT06885034Gastrointestinal Neoplasms
DrugRisvutatug Rezetecan
GlaxoSmithKline
Phase 1/2
451
Bochum, Düsseldorf, Frankfurt, Lübeck, München
2025-06-11
Active, closed
A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)
NCT06782373VEXAS, VEXAS Syndrome
DrugPacritinib
Swedish Orphan Biovitrum
Phase 2
156
Tübingen, Munich, Hamburg, Düsseldorf, Dresden, Lübeck
2025-05-28
Recruiting
EURO-STIM Registry
NCT06971796Obstructive Sleep Apnea, Obstructive Sleep Apnea (OSA)
Inspire Medical Systems, Inc.
Observational
1,000
Hamburg, Lübeck, Magdeburg, Mannheim, Munich
2025-05-26
Recruiting
Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation
NCT06830798Delayed Graft Function, DGF, Kidney Transplant
DrugRavulizumab
Alexion Pharmaceuticals, Inc.
Phase 3
450
Berlin, Erlangen, Lübeck, Mainz Am Rhein, Münster
2025-05-19
Recruiting
Validity of ICU Clinician's Appraisal of Proportionality in CPR
NCT07026773Cardiac Arrest, Out-Of-Hospital
University Hospital, Ghent
Observational
1,000
Lübeck
2025-05-18
Recruiting
Optimizing Reperfusion to Improve Outcomes and Neurologic Function
NCT06990867Acute Ischemic Stroke
Corxel Pharmaceuticals
Phase 2/3
740
Altenburg, Frankfurt, Leipzig, Lübeck, Trier
2025-05-15
Recruiting
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
NCT06925737Prostate Cancer, Prostatic Neoplasms
DrugsIfinatamab Deruxtecan·Prednisolone·Prednisone·Docetaxel
Merck Sharp & Dohme LLC
Phase 3
1,440
Nürtingen, Stuttgart, Munich, Nuremberg, Frankfurt am Main, Cologne, Duisburg, Lübeck
2025-05-13
Recruiting
Randomized Controlled Trial of Remote Symptoms Monitoring With Resilience PRO Compared to Care As Usual Only
NCT06867705Cancer
Resilience
Phase 3
1,458
Augsburg, Bad Saarow, Bochum, Hamburg, Hanover, Hösbach, Kiel, Lübeck
2025-04-01
Recruiting
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
NCT06883305Chronic Obstructive Pulmonary Disease (COPD)
DrugTezepelumab
AstraZeneca
Phase 3
990
Bendorf, Berlin, Haltern am See, Hanover, Immenhausen, Lübeck, Marburg, Rosenheim
2025-03-18
Active, closed
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
NCT06764485Metastatic Castration-resistant Prostate Cancer
DrugsAbiraterone·Enzalutamide·Docetaxel
Celgene
Phase 3
960
Nürtingen, München, Lübeck, Jena, Bonn, Essen, Hamburg, Heidelberg
2025-03-13
Recruiting
Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis
NCT06517875Primary Myelofibrosis, Myelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis
DrugsMomelotinib·Reblozyl·Luspatercept
GlaxoSmithKline
Phase 2
68
Essen, Jena, Lübeck, Mannheim
2025-02-28
Recruiting
Same-Day Discharge Versus Overnight Stay Following Pulmonary Vein Isolation for Atrial Fibrillation
NCT06598280Atrial Fibrillation
University of Luebeck
Not applicable
270
Lübeck
2025-02-20
Not yet open
A Reminder App to Optimize Bladder Filling in Patients with Prostate Cancer Receiving HYPO-fractionated Radiotherapy
NCT06784115Prostate Cancer Patients Treated by Radiotherapy
University Hospital Schleswig-Holstein
Not applicable
27
Hanover, Lübeck
2025-02-15
Recruiting
Long-term Evaluation of the SIMEOX Device at Home in Non-cystic Fibrosis Bronchiectasis
NCT06487273Non-cystic Fibrosis Bronchiectasis
Physio-Assist
Not applicable
622
Aachen, Lübeck, München
2025-02-03
Recruiting
Myval TransAXillary Transcatheter Aortic Valve Replacement Multicenter Clinical Registry
NCT06493994Aortic Valve Stenosis
University of Luebeck
Observational
100
Lübeck
2025-01-01
Recruiting
MYVAL Transcatheter Heart Valve System - Prospective German Multicenter Registry
NCT06804148Aortic Valve Stenosis
Prof. Dr. med. Ingo Eitel
Observational
2,000
Lübeck
2025-01-01
Recruiting
Dermatitis During Adjuvant Irradiation for BREAst Cancer:
NCT06483477Breast Cancer Female
University Hospital Schleswig-Holstein
Not applicable
268
Hanover, Schwerin, Flensburg, Lübeck
2024-12-23
Active, closed
A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor Neuropathy
NCT06742190Multifocal Motor Neuropathy (MMN), MMN
DrugsEmpasiprubart·Immunoglobulin·IVIG
argenx
Phase 3
154
Essen, Göttingen, Lübeck, Münster, Potsdam, Würzburg
2024-12-18
Recruiting
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
NCT06679101Multiple Myeloma, Newly Diagnosed Multiple Myeloma
DrugsBelantamab mafodotin·Daratumumab·Lenalidomide·Dexamethasone
GlaxoSmithKline
Phase 3
520
Jena, Lübeck, Chemnitz, Cologne, Dresden, Hamburg, Hanover, Mainz
2024-12-16
Active, closed
A Study to Evaluate the Safety, Tolerability, and Effects on Blood and Urine Markers of Single Ascending Dose of GSK4771261 in Healthy Participants and Participants With Autosomal Dominant Polycystic Kidney Disease
NCT06734234Kidney Disease
GlaxoSmithKline
Phase 1
86
Cologne, Lübeck
2024-12-11
By invitation
Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial)
NCT06723106Antiphospholipid Syndrome (APS), Bullous Pemphigoid (BP), Behçet's Syndrome (BS), Dermatomyositis (DM)
DrugRAY121
Chugai Pharmaceutical
Phase 1
144
Tübingen, Erlangen, Sachsen, Göttingen, Lübeck
2024-12-09
Active, closed
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)
NCT06691984Metastatic Castration-resistant Prostate Cancer
DrugsXaluritamig·Cabazitaxel·Abiraterone·Enzalutamide
Amgen
Phase 3
707
Berlin, Dresden, Düsseldorf, Essen, Hamburg, Heidelberg, Jena, Lübeck
2024-12-09
Recruiting
A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis
NCT06655155Systemic Sclerosis (SSc)
argenx
Phase 2
81
Bad Bramstedt, Lübeck, Minden, Tübingen
2024-11-11
Active, closed
Abbott Medical - VERITAS Study
NCT06707688Atrial Fibrillation (AF), Stoke
Abbott Medical Devices
Not applicable
458
Frankfurt am Main, Berlin, Lübeck, Zwickau
2024-11-07
Active, closed
Pneumonitis in Older Lung Cancer Patients After Radiotherapy
NCT06480734Lung Cancer
University Hospital Schleswig-Holstein
Not applicable
62
Hanover, Schwerin, Flensburg, Lübeck
2024-11-06
Active, closed
Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis
NCT06655896Scleroderma, Diffuse
DrugsRapcabtagene autoleucel·Rituximab
Novartis Pharmaceuticals
Phase 2
96
Freiburg im Breisgau, Göttingen, Leipzig, Halle, Jena, Berlin, Lübeck, Mainz
2024-10-29
Active, closed
Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)
NCT06602193Parkinson Disease
Denali Therapeutics Inc.
Phase 2
50
Dresden, Lübeck, Tübingen
2024-10-24
Active, closed
A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS)
NCT06643481Amyotrophic Lateral Sclerosis (ALS)
DrugVHB937
Novartis Pharmaceuticals
Phase 2
251
Mannheim, Munich, Würzburg, Rostock, Berlin, Hanover, Lübeck, Münster
2024-10-17
Active, closed
Study to Assess the Efficacy, Safety, and Tolerability of NOC-110 in Adults With Refractory or Unexplained Chronic Cough
NCT06504446Refractory or Unexplained Chronic Cough
Nocion Therapeutics
Phase 2
455
Munich, Darmstadt, Frankfurt am Main, Marburg, Halle, Geesthacht, Lübeck, Berlin
2024-09-24
Active, closed
A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)
NCT06581198Lupus Erythematosus, Systemic, Lupus Nephritis
DrugRapcabtagene autoleucel
Novartis Pharmaceuticals
Phase 2
179
Stuttgart, Frankfurt am Main, Cologne, Leipzig, Jena, Essen, Lübeck, Mainz
2024-09-04
Recruiting
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
NCT06528314NASH - Nonalcoholic Steatohepatitis, MASH - Metabolic Dysfunction-Associated Steatohepatitis
DrugEfruxifermin
Akero Therapeutics, Inc
Phase 3
2,150
Frankfurt am Main, Homburg, Leipzig, Lübeck, Berlin
2024-09-04
Recruiting
Endoscopic Radiofrequency Ablation for Unresectable Cholangiocarcinoma
NCT06175845Cholangiocarcinoma, Klatskin Tumor, Bile Duct Cancer, Liver Cancer
Universitätsklinikum Hamburg-Eppendorf
Not applicable
130
Berlin, Bonn, Chemnitz, Essen, Hamburg, Hanover, Heidelberg, Lübeck
2024-08-30
Active, closed
Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma
NCT06572228Asthma
DrugsICS/LABA·Dupilumab
Regeneron Pharmaceuticals
Phase 4
120
Augsburg, Munich, Frankfurt am Main, Koblenz, Lübeck, Berlin, Leipzig, Mainz
2024-08-26
Recruiting
Durvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extrahepatic Cholangiocarcinoma
NCT06440993Extrahepatic Cholangiocarcinoma, Unresectable Perihilar or Ductal CCA
DrugsDurvalumab·Gemcitabine·Cisplatin
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2
42
Aachen, Bonn, Cologne, Düsseldorf, Frankfurt, Göttingen, Hanover, Lübeck
2024-08-23
Recruiting
Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
NCT06371417Antiphospholipid Syndrome (APS), Bullous Pemphigoid (BP), Behçet's Syndrome (BS), Dermatomyositis (DM)
DrugRAY121
Chugai Pharmaceutical
Phase 1
144
Tübingen, Erlangen, Rüdersdorf, Sachsen, Göttingen, Lübeck
2024-08-19
Recruiting
Multicentre Study for Data Collection, Development, and Evaluation of Novel CRC Screening and Diagnostic Methods
NCT06515821Colorectal Cancer
Firalis SA
Observational
4,100
Lübeck, Mainz-GE
2024-08-01
Recruiting
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
NCT06282575Biliary Tract Cancer
DrugsZanidatamab·Durvalumab·Gemcitabine·Cisplatin
Jazz Pharmaceuticals
Phase 3
286
Freiburg im Breisgau, Heidelberg, Tübingen, München, Frankfurt am Main, Hanover, Dresden, Lübeck
2024-07-19
Recruiting
Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
NCT06463587Generalized Myasthenia Gravis
DrugCladribine
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Phase 3
264
Ulm, Göttingen, Hanover, Bochum, Düsseldorf, Dresden, Leipzig, Lübeck
2024-06-25
Recruiting
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
NCT06422143Non-small Cell Lung Cancer, NSCLC
DrugsSacituzumab tirumotecan·Nab-paclitaxel·Keytruda·Paclitaxel
Merck Sharp & Dohme LLC
Phase 3
851
Dortmund, Essen, Lübeck, Gera, Berlin
2024-06-10
Active, closed
A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE)
NCT06411249Systemic Lupus Erythematosus
DrugBelimumab
GlaxoSmithKline
Phase 4
303
Herne, Lübeck, Mainz, Meerbusch
2024-06-06
Active, closed
The OPBC-07/microNAC Study
NCT06529302Breast Cancer
University Hospital, Basel, Switzerland
Observational
2,000
Augsburg, Düsseldorf, Essen, Heidelberg, Lübeck
2024-05-15
Recruiting
Early Closure of Left Atrial Appendage for Patients With Atrial Fibrillation and Ischemic Stroke Despite Anticoagulation Therapy
NCT05976685Ischemic Stroke, Atrial Fibrillation
DrugDOAC
Insel Gruppe AG, University Hospital Bern
Not applicable
482
Lübeck, Berlin, Bonn, Göttingen, Hamburg, Heidelberg, Leipzig, Mannheim
2024-05-01
Recruiting
A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)
NCT06338995Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
DrugLebrikizumab
Eli Lilly and Company
Phase 3
510
Berlin, Dresden, Frankfurt am Main, Jena, Lübeck, Sachsen
2024-04-29
Active, closed
A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)
NCT06211764Non-Muscle Invasive Bladder Neoplasms
DrugsTAR-200·Mitomycin C·Gemcitabine
Janssen Research & Development, LLC
Phase 3
272
Cologne, Halle, Leverkusen, Lübeck, Mettmann, München
2024-04-09
Recruiting
Improvement of Quality of Life by Cannabinoids in Oncologic Patients
NCT06097533Medical Oncology, Palliative Care, Quality of Life, Cannabinoids
University Hospital Schleswig-Holstein
Phase 2
170
Hamburg, Kiel, Lübeck
2024-04-08
Active, closed
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor
NCT06241118Dermatitis Atopic
DrugsPimecrolimus·Amlitelimab·Tacrolimus
Sanofi
Phase 3
464
Berlin, Blankenfelde-Mahlow, Dresden, Frankfurt, Lübeck, Witten
2024-02-29
Active, closed
Study to Assess Speed of Onset and Durability of Effectiveness of Upadacitinib in Adult Participants With Moderate to Severe Crohn's Disease (CD) in Real World Clinical Practice.
NCT05930275Crohn's Disease
AbbVie
Observational
1,200
Dachau, Lüneburg, Oldenburg, Minden, Buedelsdorf, Lübeck, Jena, Berlin
2024-02-19
Recruiting
A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients
NCT06008197Heart Failure, Acute Heart Failure
DrugFinerenone
Colorado Prevention Center
Phase 3
5,200
Lübeck, Berlin, Jena, Dresden, Giessen, Regensburg
2024-01-17
Recruiting
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
NCT06136624Prostate Cancer Metastatic
DrugsFludrocortisone acetate·Opevesostat·Zytiga·Hydrocortisone
Merck Sharp & Dohme LLC
Phase 3
1,310
Munich, Schwerin, Bonn, Münster, Lübeck, Jena, Berlin, Hamburg
2023-12-31
Recruiting
BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT
NCT06059638Hypertension, Hypertension, Systolic, Hypertension, Essential
Orchestra BioMed, Inc
Not applicable
316
Berlin, Bonn, Frankfurt, Hamburg, Leipzig, Lübeck, Mannheim, Saarbrücken
2023-12-27
Active, closed
A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma
NCT06007690Choroidal Melanoma, Indeterminate Lesions, Uveal Melanoma, Ocular Melanoma
DrugBel-sar
Aura Biosciences
Phase 3
108
Berlin, Cologne, Essen, Hamburg, Lübeck, München, Tübingen
2023-12-06
Recruiting
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
NCT06106945Multiple Myeloma
DrugsElranatamab·Pomalidomide·Dexamethasone
AstraZeneca
Phase 1/2
226
Essen, Freiburg im Breisgau, Hamburg, Heidelberg, Lübeck, Nuremberg, Tübingen, Würzburg
2023-12-05
Recruiting
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
NCT06215716NASH With Fibrosis, MASH With Fibrosis
DrugEfruxifermin
Akero Therapeutics, Inc
Phase 3
1,650
Würzburg, Frankfurt am Main, Mainz, Homburg, Leipzig, Lübeck, Berlin
2023-12-01
Active, closed
Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)
NCT06073821CLL
DrugsSonrotoclax·Zanubrutinib·Obinutuzumab·Venetoclax
BeOne Medicines
Phase 3
652
Berlin, Frankfurt am Main, Lübeck
2023-11-11
Active, closed
A Study to Estimate How Often Post-stroke Spasticity Occurs and to Provide a Standard Guideline on the Best Way to Monitor Its Development
NCT06055725Spasticity as Sequela of Stroke
Ipsen
Observational
1,057
Altenburg, Berlin, Dresden, Düsseldorf, Essen, Kiel, Lübeck, Mainz
2023-11-01
Recruiting
SGLT2 Inhibition in Addition to Lifestyle Intervention and Risk for Complications in Subtypes of Patients With Prediabetes
NCT06054035Type2diabetes, PreDiabetes, Renal Failure
DrugDapagliflozin
University Hospital Tuebingen
Phase 4
170
Berlin, Dresden, Düsseldorf, Heidelberg, Leipzig, Lübeck, München, Tübingen
2023-10-26
Recruiting
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
NCT05899608Non-Small Cell Lung Cancer
DrugsIvonescimab·Pembrolizumab
Summit Therapeutics
Phase 3
1,600
Esslingen am Neckar, Frankfurt, Gauting, Giesen, Heidelberg, Jena, Kempten, Lübeck
2023-10-26
Active, closed
VOLT CE Mark Study
NCT06106594Atrial Arrhythmia, Atrial Fibrillation, Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation
Abbott Medical Devices
Not applicable
300
Lübeck
2023-10-24
Active, closed
ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions
NCT05949684Myelodysplastic Syndromes
DrugsEpoetin Alfa·Reblozyl·Luspatercept
Bristol-Myers Squibb
Phase 3
402
Erding, Münster, Koblenz, Leipzig, Jena, Berlin, Düsseldorf, Lübeck
2023-10-24
Recruiting
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata
NCT06012240Alopecia Areata
DrugUpadacitinib
AbbVie
Phase 3
1,500
Munich, Bad Bentheim, Düsseldorf, Münster, Lübeck, Berlin
2023-10-11
Recruiting
Global Multicenter Registry on Transcatheter TRIcuspid Valve RePLACEment
NCT06033274Tricuspid Regurgitation
Montefiore Medical Center
Observational
800
Munich, Frankfurt am Main, Essen, Lübeck, Bad Oeynhausen, Cologne, Hamburg
2023-10-05
Recruiting
A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
NCT05730036Relapsed Refractory Multiple Myeloma (RRMM)
DrugsElotuzumab·Linvoseltamab·Pomalidomide·Dexamethasone
Regeneron Pharmaceuticals
Phase 3
410
Tübingen, Lübeck, Hamburg, Leipzig
2023-09-18
Recruiting
Rescue of Nephrons With ALE.F02 (RENAL-F02)
NCT06047171Glomerulonephritis Rapidly Progressive
DrugsCyclophosphamid·Rituximab
Alentis Therapeutics AG
Phase 2
80
Berlin, Cologne, Dresden, Essen, Hanover, Leipzig, Lübeck, München
2023-09-07
Active, closed
A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC
NCT05884398Metastatic Castrate-sensitive Prostate Cancer
DrugApalutamide
Janssen Research & Development, LLC
Phase 3
420
Aachen, Augsburg, Cologne, Dresden, Lübeck, München, Nürtingen, Würzburg
2023-08-31
Active, closed
Effects of Sedation, TEmperature and Pressure After Cardiac Arrest and REsuscitation on Major Adverse Kidney Events (STEPCARE-MAKE)
NCT07579390Acute Kidney Failure, Renal Replacement Therapy for Acute Kidney Injury in ICU, Sedation in Intensive Care Unit Patients, Sedation in the ICU
Helsinki University Central Hospital
Not applicable
3,500
Berlin, Lübeck, Tübingen
2023-08-17
Active, closed
Sedation, Temperature and Pressure After Cardiac Arrest and Resuscitation
NCT05564754Cardiac Arrest With Successful Resuscitation, Hypoxia, Brain
Region Skane
Not applicable
3,500
Berlin, Lübeck, Tübingen
2023-08-17
Recruiting
Stepcare Extended Follow-up Substudy
NCT06207942Cardiac Arrest With Successful Resuscitation, Hypoxia, Brain, Cognitive Impairment, Caregiver Burden
Region Skane
Not applicable
600
Berlin, Lübeck, Tübingen
2023-08-01
Recruiting
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
NCT05855200Colonic Neoplasms, Neoplasms, Colon
DrugsCapeox·Dostarlimab·Folfox
GlaxoSmithKline
Phase 3
892
Berlin, Düsseldorf, Frankfurt, Halle, Lübeck, Mannheim, München
2023-08-01
Recruiting
Combination Treatment of Belantamab Mafodotin and Venetoclax in Treatment of Relapsed and Refractory t(11;14) Multiple Myeloma
NCT05853965Multiple Myeloma, Multiple Myeloma in Relapse
Universitätsklinikum Hamburg-Eppendorf
Phase 1/2
45
Hamburg, Chemnitz, Heidelberg, Lübeck, Ulm
2023-06-28
Active, closed
Tilrdakizumab Almirall
NCT07244744Psoriasis
DrugTildrakizumab
University Hospital Schleswig-Holstein
Observational
3
Lübeck
2023-06-27
Active, closed
Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)
NCT05883644Advanced Hepatocellular Carcinoma
DrugsTremelimumab·Durvalumab
AstraZeneca
Phase 3
111
Berlin, Cologne, Frankfurt, Lübeck
2023-06-27
Recruiting
PredIcting sterOid depeNdEnt livEr injuRy With Polyreactive Immunoglobulin G
NCT05810480Autoimmune Hepatitis, Autoimmune Liver Disease
Hannover Medical School
Observational
400
Aachen, Hamburg, Hanover, Heidelberg, Lübeck, Rostock
2023-06-06
Recruiting
Multicentre Implementation and Validation of a Molecular Diagnostic for VitreoRetinal Lymphoma
NCT05841914Vitreoretinal Lymphoma
Vinodh Kakkassery, MD
Observational
220
Lübeck
2023-06-01
Active, closed
Dose Optimization and Expansion Study of DFV890 in Adult Patients With Myeloid Diseases
NCT05552469Myeloid Diseases
Novartis Pharmaceuticals
Phase 1
71
Dresden, Leipzig, Lübeck
2023-05-08
Recruiting
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
NCT05727904Metastatic Melanoma, Unresectable Melanoma, Melanoma
DrugsLifileucel·Pembrolizumab
Iovance Biotherapeutics, Inc.
Phase 3
670
Berlin, Würzburg, Dresden, Hamburg, Lübeck, Munich
2023-03-30
Active, closed
Frespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC Stimulator) in Adults With PH-COPD
NCT05612035Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
Merck Sharp & Dohme LLC
Phase 2
129
Heidelberg, Giessen, Hanover, Dresden, Lübeck
2023-03-16
Active, closed
An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH)
NCT05649748Pulmonary Arterial Hypertension
DrugTreprostinil Palmitil
Insmed Incorporated
Phase 2/3
91
Heidelberg, München, Lübeck
2023-03-07
Active, closed
A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma
NCT05625399Melanoma
DrugsHyqvia·Relatlimab·Nivolumab
Bristol-Myers Squibb
Phase 3
579
Heidelberg, Ulm, Regensburg, Lübeck, Berlin, Buxtehude, Dortmund, Erfurt
2023-03-06
Active, closed
Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD
NCT05711940Treatment Resistant Depression
DrugPsilocybin
COMPASS Pathways
Phase 3
572
Berlin, Frankfurt, Lübeck
2023-02-14
Active, closed
GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease
NCT05686551Huntington Disease
Hoffmann-La Roche
Phase 2
301
Aachen, Berlin, Bochum, Bonn, Erlangen, Lübeck, Taufkirchen, Ulm
2023-02-03
Recruiting
Expression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients
NCT05665140Newly Diagnosed Multiple Myeloma
DrugsVelcade·Isatuximab·Bortezomib·Lenalidomide
University Hopsital Schleswig Holstein Campus Lübeck
Phase 2/3
100
Berlin, Bielefeld, Hamburg, Lübeck, Münster, Würzburg
2023-02-03
Active, closed
A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)
NCT05617677Systemic Lupus Erythematosus
DrugDeucravacitinib
Bristol-Myers Squibb
Phase 3
516
Tübingen, Munich, Dresden, Lübeck, Chemnitz, Cologne, Erlangen, Planegg
2023-01-12
Recruiting
Alleviant ALLAY-HF Study
NCT05685303Heart Failure
Alleviant Medical, Inc.
Not applicable
700
Hamburg, Lübeck, Magdeburg
2023-01-10
Recruiting
MEthods for LOcalization of Different Types of Breast Lesions
NCT05559411Breast Cancer
European Breast Cancer Research Association of Surgical Trialists
Observational
7,416
Lübeck
2023-01-01
Active, closed
A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease
NCT05595642Chronic Obstructive Pulmonary Disease (COPD)
DrugAstegolimab
Hoffmann-La Roche
Phase 3
1,290
Lübeck, Berlin, Darmstadt, Frankfurt, Hamburg, Hanover, Heidelberg, Immenhausen
2022-12-29
By invitation
Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema
NCT05396105Hereditary Angioedema, Hereditary Angioedema Type I, Hereditary Angioedema Type II, Hereditary Angioedema Types I and II
DrugDeucrictibant
Pharvaris Netherlands B.V.
Phase 2/3
150
Berlin, Frankfurt am Main, Lübeck
2022-12-28
Active, closed
A Study Evaluating the Safety and Tolerability of QRL-201 in ALS
NCT05633459Amyotrophic Lateral Sclerosis
QurAlis Corporation
Phase 1
69
Bonn, Berlin, Lübeck, Ulm
2022-12-16
Active, closed
TARGET Study: Safety and Performance of the Cardiovalve TR Replacement System
NCT05486832Tricuspid Regurgitation
Cardiovalve Ltd.
Not applicable
157
Bad Oeynhausen, Berlin, Bonn, Cologne, Hamburg, Lübeck, Regensburg
2022-12-09
Active, closed
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)
NCT05501886Breast Cancer
DrugsGedatolisib·Alpelisib·Palbociclib·Fulvestrant
Celcuity Inc
Phase 3
701
Bayreuth, Berlin, Dorf Mecklenburg, Lübeck, Mainz, Münster, Saarbrücken, Wuppertal
2022-12-08
Active, closed
A Study of Distal Jejunal-release Dextrose in Obese Participants
NCT05385978Obese
Aphaia Pharma US LLC
Phase 2
150
Lübeck, Neuruppin
2022-11-01
Active, closed
Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer
NCT05502237Non-small Cell Lung Cancer
DrugsDomvanalimab·Zimberelimab·Nab-paclitaxel·Pemetrexed
Gilead Sciences
Phase 3
1,021
Cologne, Essen, Großhansdorf, Halle, Hamburg, Hemer, Karlsruhe, Lübeck
2022-10-12
Recruiting
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
NCT05243797Multiple Myeloma
DrugsTeclistamab·Lenalidomide
European Myeloma Network B.V.
Phase 3
1,594
Hamburg, Heidelberg, Jena, Lübeck, München, Nuremberg, Tübingen, Würzburg
2022-09-08
Active, closed
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
NCT05382299Triple Negative Breast Cancer, PD-L1 Negative
DrugsAbraxane·Sacituzumab Govitecan·Nab-paclitaxel·Gemcitabine
Gilead Sciences
Phase 3
623
Berlin, Bonn, Cologne, Essen, Hamburg, Heidelberg, Lübeck, Mannheim
2022-07-20
Active, closed
STAR-LIFE: a Post-market Registry on MINIject
NCT05269680Open Angle Glaucoma
iSTAR Medical
Observational
320
Bochum, Düsseldorf, Hamburg, Kiel, Lübeck, Ulm
2022-07-20
By invitation
ORACLE: A Long-term Follow-up Study to Evaluate the Safety of GT005 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration Treated in a Gyroscope-sponsored Antecedent Study
NCT05481827Age Related Macular Degeneration (AMD)
Gyroscope Therapeutics Limited
Phase 2
225
Lübeck, Tübingen
2022-07-12
Active, closed
Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
NCT04975997Multiple Myeloma
DrugsIberdomide·Bortezomib·Daratumumab·Dexamethasone
Celgene
Phase 3
939
Kiel, Frankfurt am Main, Hamburg, Heidelberg, Lübeck
2022-06-23
Active, closed
SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM
NCT05405166Plasma Cell Myeloma Recurrent
DrugsParacetamol / Acetaminophen·Montelukast·Diphenhydramine·Isatuximab
Sanofi
Phase 3
531
Dresden, Heidelberg, Lübeck, Nuremberg
2022-06-23
Recruiting
A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB
NCT05183646FSGS
DrugRepagermanium
Dimerix Bioscience Pty Ltd
Phase 3
286
Aachen, Cologne, Dresden, Hamburg, Hanover, Lübeck, Mainz, Villingen-Schwenningen
2022-05-30
Active, closed
Comparing PFO Outcomes of the Occlutech Flex II PFO Occluder to Standard of Care PFO Occlusion
NCT05069558Stroke, Patent Foramen Ovale, PFO
Occlutech International AB
Not applicable
450
Hamburg, Frankfurt, Heidelberg, Lübeck
2022-05-09
Recruiting
Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma and Follicular Lymphoma
NCT05326308Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma, Follicular Lymphoma
DrugsZanubrutinib·Obinutuzumab
iOMEDICO AG
Observational
845
Lübeck
2022-04-26
Recruiting
Left Atrial Appendage Closure in Patients With Non-valvular Atrial Fibrillation and End-stage Chronic KIDNEY Disease
NCT05204212Non-valvular Atrial Fibrillation (NVAF): Paroxysmal, Persistent, Permanent
Prof. Dr. med. Ingo Eitel
Not applicable
430
Lübeck
2022-03-28
Active, closed
Ovarian PRP (Platelet Rich Plasma) Injection for Follicular Activation
NCT05279560Premature Ovarian Insufficiency, Infertility, Female, Sterility, Female, PRP
University of Luebeck
Not applicable
114
Lübeck
2022-03-17
Active, closed
A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection
NCT05120349Non-Small Cell Lung Cancer
DrugsTagrisso·Osimertinib
AstraZeneca
Phase 3
390
Berlin, Esslingen am Neckar, Georgsmarienhütte, Lübeck, München, Würzburg
2022-02-21
Recruiting
Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
NCT04879043Multiple Myeloma, Plasma Cell Disorder
DrugHDP-101
Heidelberg Pharma AG
Phase 1/2
78
Berlin, Chemnitz, Cologne, Hamburg, Heidelberg, Kiel, Lübeck, Mainz
2022-02-07
Active, closed
Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.
NCT05038735Breast Cancer
DrugsAlpelisib·Fulvestrant
Novartis Pharmaceuticals
Phase 3
210
Cologne, Augsburg, Berlin, Essen, Lübeck
2021-12-17
Recruiting
RFC1 Natural History Study
NCT05177809Ataxia
Prof. Dr. Matthis Synofzik
Observational
150
Tübingen, Bonn, Lübeck
2021-12-14
Recruiting
Real-world Evidence on Follitropin Delta Individual Dosing
NCT05173597Infertility, Sterility
DrugFollitropin delta
University of Luebeck
Observational
850
Lübeck
2021-12-08
Recruiting
A Comparison of Two Psychotherapy Programs in Persistently Depressed Treatment-Resistant Inpatients
NCT04996433Persistent Depressive Disorder, Treatment-resistant Depression
University of Greifswald
Not applicable
396
Berlin, Bonn, Hanover, Jena, Lübeck, Marburg, München, Tübingen
2021-12-01
Active, closed
Registry for Patients Undergoing Penile Prosthesis Implantation for Male Erectile Dysfunction
NCT03849586Erectile Dysfunction
European Association of Urology Research Foundation
Observational
1,076
Essen, Lübeck
2021-11-19
Active, closed
Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT05089734Non-Small Cell Lung Cancer
DrugsSacituzumab Govitecan·Docetaxel
Gilead Sciences
Phase 3
603
Braunschweig, Esslingen am Neckar, Hamburg, Heilbronn, Immenhausen, Kassel, Lübeck, Mannheim
2021-11-17
Recruiting
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
NCT04996875Advanced Systemic Mastocytosis (AdvSM), SM With an Associated Hematologic Neoplasm (SM-AHN), Mast Cell Leukemia (MCL), Aggressive Systemic Mastocytosis (ASM)
DrugBezuclastinib
Cogent Biosciences, Inc.
Phase 2
140
Aachen, Freiburg im Breisgau, Lübeck, Mannheim
2021-11-09
Active, closed
SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN
NCT05198674Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases
Medtronic Vascular
Not applicable
1,899
Erlangen, Giessen, Homburg, Leipzig, Lübeck
2021-10-20
Active, closed
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
NCT04971226Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive
DrugsBosutinib·ABL001·Asciminib·Nilotinib
Novartis Pharmaceuticals
Phase 3
405
Mannheim, Frankfurt am Main, Jena, Aachen, Berlin, Lübeck
2021-10-06
Recruiting
ContraBand™: Safety & Feasibility Study (RM-20-01)
NCT05230745Heart Failure, Left Sided
Restore Medical Ltd
Not applicable
55
Lübeck
2021-09-28
Recruiting
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
NCT05006716B-cell Malignancy, Marginal Zone Lymphoma, Follicular Lymphoma, Non-Hodgkin Lymphoma
DrugTacabrutideg
BeOne Medicines
Phase 1/2
645
Cologne, Dresden, Leipzig, Lübeck, Mainz, München, Ulm
2021-09-13
Recruiting
Interventional Structural Registry - LuEbeck
NCT06977139Structural Heart Disease
Prof. Dr. med. Ingo Eitel
Observational
2,000
Lübeck
2021-09-11
Active, closed
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )
NCT04849728NASH - Nonalcoholic Steatohepatitis
Inventiva Pharma
Phase 3
1,000
Wiesbaden, Mainz, Homburg, Chemnitz, Dresden, Leipzig, Lübeck, Berlin
2021-08-19
Active, closed
Ultrasound-facilitated, Catheter-directed, Thrombolysis in Intermediate-high Risk Pulmonary Embolism
NCT04790370Pulmonary Embolism
Boston Scientific Corporation
Phase 4
544
Aachen, Bielefeld, Bonn, Chemnitz, Freiburg im Breisgau, Immenstädt, Lübeck, Mainz
2021-08-02
Recruiting
A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
NCT04951622Myasthenia Gravis
DrugNipocalimab
Janssen Research & Development, LLC
Phase 3
199
Berlin, Göttingen, Leipzig, Lübeck, Ulm, Wiesbaden
2021-07-15
Active, closed
Remote Ischemic Conditioning With Local Ischemic Postconditioning in High-Risk ST-elevation Myocardial Infarction
NCT04844931ST Elevation Myocardial Infarction
Helios Health Institute GmbH
Not applicable
250
Bremen, Dresden, Düsseldorf, Essen, Hamburg, Leipzig, Ludwigshafen, Lübeck
2021-07-05
Recruiting
WE-TRUST (Workflow Optimization to Reduce Time to Endovascular Reperfusion for Ultra-fast Stroke Treatment)
NCT04701684Stroke, Acute
Philips Clinical & Medical Affairs Global
Not applicable
594
Bonn, Kassel, Lübeck, Munich
2021-06-23
Active, closed
HANSE - Holistic Implementation Study Assessing a Northern German Interdisciplinary Lung Cancer Screening Effort
NCT04913155Lung Cancer
Hannover Medical School
Not applicable
12,100
Hanover, Großhansdorf, Lübeck
2021-05-20
Recruiting
Intermittent Fasting to Improve Insulin Secretion
NCT04607096PreDiabetes, Diabetes type2, Intermittent Fasting, Insulin Secretion
University Hospital Tuebingen
Not applicable
200
Berlin, Dresden, Düsseldorf, Heidelberg, Leipzig, Lübeck, Munich, Tübingen
2021-04-08
Active, closed
Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)
NCT04662255Lymphoma, Mantle-Cell
DrugsPirtobrutinib·Ibrutinib·Acalabrutinib·Zanubrutinib
Loxo Oncology, Inc.
Phase 3
500
Ulm, Würzburg, Giessen, Münster, Koblenz, Mainz, Lübeck, Hamburg
2021-04-08
Active, closed
SMall Annuli Randomized To Evolut™ or SAPIEN™ Trial
NCT04722250Symptomatic Aortic Stenosis, Aortic Valve Stenosis, Aortic Valve Replacement
Medtronic Cardiovascular
Not applicable
1,103
Bad Oeynhausen, Berlin, Dortmund, Düsseldorf, Kiel, Leipzig, Lübeck, München
2021-04-02
Active, closed
Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)
NCT04822181Non-alcoholic Steatohepatitis
DrugSemaglutide
Novo Nordisk A/S
Phase 3
1,205
Berlin, Bochum, Bonn, Frankfurt, Hanover, Leipzig, Lübeck, Magdeburg
2021-04-01
Recruiting
CRP Apheresis in STEMI
NCT04939805ST Elevation Myocardial Infarction, C-Reactive Protein, Apheresis, Myocardial Injury
Medical University Innsbruck
Not applicable
202
Lübeck, Leipzig
2021-04-01
Active, closed
A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)
NCT04817007Myelofibrosis
DrugsBMS-986158·Fedratinib·Ruxolitinib
Bristol-Myers Squibb
Phase 1/2
216
Erding, Essen, Chemnitz, Halle, Lübeck
2021-03-22
Active, closed
Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT04666038Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
DrugsIdelalisib·Truxima·Pirtobrutinib·Bendamustine
Loxo Oncology, Inc.
Phase 3
238
Heidelberg, Ulm, Kerpener, Langenbeckstraße 1, Koelner Platz 1, Kiel, Lübeck, Berlin
2021-03-09
Recruiting
Isatuximab in Combination With Novel Agents in RRMM - Master Protocol
NCT04643002Plasma Cell Myeloma Refractory
DrugsEvorpacept·Belumosudil·Belantamab mafodotin·Isatuximab
Sanofi
Phase 1/2
258
Frankfurt, Lübeck
2021-01-25
Recruiting
Cardiac Magnetic Resonance Guidance of Implantable Cardioverter Defibrillator Implantation in Non-ischemic Dilated Cardiomyopathy
NCT04558723Non-ischemic Dilated Cardiomyopathy
Prof. Dr. med. Ingo Eitel
Not applicable
760
Lübeck
2021-01-14
Active, closed
Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
NCT04634877Endometrial Neoplasms
DrugsDocetaxel·Keytruda·Paclitaxel·Cisplatin
Merck Sharp & Dohme LLC
Phase 3
990
Heilbronn, Ludwigsburg, Tübingen, Hanover, Bonn, Essen, Dresden, Lübeck
2021-01-10
Recruiting
HIPEC + FLOT vs. FLOT Alone in Patients With Gastric Cancer and GEJ (PREVENT)
NCT04447352Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
DrugsCalciumfolinat·Leucovorin·Adrucil·Docetaxel
Krankenhaus Nordwest
Phase 3
200
Aachen, Dresden, Frankfurt, Halle, Leipzig, Ludwigsburg, Lübeck, Magdeburg
2020-12-17
Active, closed
Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC
NCT04522544Hepatocellular Carcinoma Non-resectable, HCC
DrugsTremelimumab·Durvalumab
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2
55
Bonn, Cologne, Essen, Göttingen, Hanover, Jena, Lübeck, München
2020-12-15
Active, closed
A Study of Inebilizumab Efficacy and Safety in IgG4- Related Disease
NCT04540497IgG4 Related Disease
DrugInebilizumab
Amgen
Phase 3
135
Berlin, Lübeck, München
2020-12-04
Active, closed
Restoration of Central Vision With the PRIMA System in Patients With Atrophic AMD
NCT04676854Geographic Atrophy
Science Corporation
Not applicable
38
Aachen, Bonn, Hamburg, Ludwigshafen am Rhein, Lübeck, Munich, Münster, Sulzbach
2020-11-24
Recruiting
Epidemiology of Sexually Transmitted Infections and Its iMpAcT on fEmale Infertility
NCT05244967Sexually Transmitted Infection
University of Luebeck
Observational
533
Lübeck
2020-11-11
Recruiting
CHoice of OptImal transCatheter trEatment for Mitral Insufficiency Registry
NCT04688190Mitral Regurgitation, Mitral Valve Disease, Mitral Annular Calcification
Universitätsklinikum Hamburg-Eppendorf
Observational
1,000
Bad Oeynhausen, Berlin, Bonn, Cologne, Frankfurt, Hamburg, Lübeck, Mainz
2020-11-01
Active, closed
Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC
NCT04446117Metastatic Prostate Cancer, Prostate Adenocarcinoma
DrugsZytiga·Xtandi·Abiraterone·Abiraterone acetate
Exelixis
Phase 3
575
Nürtingen, Duisburg, Gütersloh, Münster, Lübeck, Berlin, Hamburg, Hanover
2020-10-19
Active, closed
CHAMPION-AF Clinical Trial
NCT04394546Atrial Fibrillation, Stroke, Bleeding
DrugsNon-Vitamin K Anticoagulant·NOAC
Boston Scientific Corporation
Not applicable
3,000
Berlin, Coburg, Dresden, Erfurt, Essen, Frankfurt, Hamburg, Lübeck
2020-10-15
Active, closed
Adjuvant Chemotherapy in Patients With Intermediate or High Risk Stage I or Stage IIA Non-squamous Non-Small Cell Lung Cancer: AIM-HIGH (Adjuvant Intervention in Molecular High Risk Patients)
NCT01817192Non-Small Cell Lung Cancer
Razor Genomics
Not applicable
420
Cologne, Gauting, Georgsmarienhütte, Großhansdorf, Hanover, Lübeck, München, Oldenburg
2020-09-11
Recruiting
AutoInflammatory Disease Alliance Registry (AIDA)
NCT05200715Hereditary Autoinflammatory Diseases, Schnitzler Syndrome, Behcet Syndrome, PFAPA Syndrome
University of Siena
Observational
3,500
Lübeck
2020-08-06
Active, closed
Amplatzer Amulet LAAO vs. NOAC
NCT04226547Atrial Fibrillation, Stroke, Bleeding
DrugNOAC
Abbott Medical Devices
Not applicable
2,650
Berlin, Lübeck, Bad Segeberg, Bonn, Frankfurt, Giessen, Mainz, Munich
2020-07-07
Recruiting
PPMI Clinical - Establishing a Deeply Phenotyped PD Cohort
NCT04477785Parkinson Disease
Michael J. Fox Foundation for Parkinson's Research
Observational
4,500
Hessen, Kassel, Lübeck, Tübingen
2020-07-01
Recruiting
Safety and Efficacy of Induced Pluripotent Stem Cell-derived Engineered Human Myocardium as Biological Ventricular Assist Tissue in Terminal Heart Failure
NCT04396899Heart Failure
University Medical Center Goettingen
Phase 1/2
53
Göttingen, Bad Oeynhausen, Lübeck
2020-02-03
Active, closed
MitraClip EXPAND G4 Study
NCT04177394Mitral Valve Regurgitation, Mitral Regurgitation
Abbott Medical Devices
Observational
1,164
Lübeck, Essen, Mainz, Dresden, Bad Krozingen, Bad Oeynhausen, Bernau, Cologne
2020-01-17
Recruiting
Additional Left Atrial Appendage Isolation During Balloon Ablation for Persistent or Long-standing Persistent Atrial Fibrillation
NCT04240366Persistent or Long-standing Persistent Atrial Fibrillation
University of Luebeck
Not applicable
350
Hamburg, Lübeck
2019-12-17
Recruiting
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
NCT04176198Myelofibrosis
DrugsMomelotinib·Ruxolitinib
Sumitomo Pharma America, Inc.
Phase 1/2
240
Halle, Lübeck
2019-12-16
Active, closed
Efficacy and Safety of Benralizumab in EGPA Compared to Mepolizumab.
NCT04157348Eosinophilic Granulomatous Vasculitis
DrugsBenralizumab·Mepolizumab
AstraZeneca
Phase 3
140
Bamberg, Freiburg im Breisgau, Hamburg, Kirchheim, Lübeck
2019-10-29
Recruiting
Phenotypes, Biomarkers and Pathophysiology in Hereditary Spastic Paraplegias and Related Disorders
NCT03981276Hereditary Spastic Paraplegia
Dr. Rebecca Schule
Observational
2,000
Bonn, Erlangen, Essen, Göttingen, Heidelberg, Lübeck, Magdeburg, München
2019-10-14
By invitation
A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)
NCT04093570Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes
DrugDecitabine
Taiho Oncology, Inc.
Phase 2
332
Braunschweig, Lübeck
2019-09-30
Active, closed
Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment
NCT03847428Hepatocellular Carcinoma
DrugsAvastin·Durvalumab·Bevacizumab
AstraZeneca
Phase 3
908
Berlin, Bonn, Chemnitz, Cologne, Freiburg im Breisgau, Heidelberg, Leipzig, Lübeck
2019-04-29
Active, closed
(PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis
NCT03731260Indolent Systemic Mastocytosis
DrugAvapritinib
Blueprint Medicines Corporation
Phase 2
251
Aachen, Berlin, Hamburg, Lübeck, Mainz, Mannheim, Munich
2019-04-16
Active, closed
Phase III Study in First-line Treatment of Patients With Metastatic Colorectal Cancer Who Are Not Candidate for Intensive Therapy.
NCT03869892Metastatic Colorectal Cancer
DrugsTrifluridine/Tipiracil·Capecitabine
Institut de Recherches Internationales Servier
Phase 3
856
Berlin, Lübeck, München
2019-03-21
Recruiting
Long-Term Real-World Outcomes Study on Patients Implanted With a Neurostimulator
NCT03876054Chronic Pain
Abbott Medical Devices
Observational
2,000
Tübingen, Ingolstadt, Cologne, Duisburg, Düsseldorf, Mönchengladbach, Lübeck, Gera
2019-03-13
Recruiting
Deep Brain Stimulation (DBS) Retrospective Outcomes Study
NCT03664609Parkinson Disease, Essential Tremor, Dystonia
Boston Scientific Corporation
Observational
5,000
Cologne, Düsseldorf, Jena, Lübeck, Würzburg
2019-03-12
Active, closed
A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study
NCT03768063Cancer
DrugsEmactuzumab·Rucaparib·Cobimetinib·Vemurafenib
Hoffmann-La Roche
Phase 3
1,000
Ulm, Regensburg, Lübeck, Essen, Freiburg im Breisgau, Gauting, Gera, Immenhausen
2019-02-28
Active, closed
A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC
NCT03661866Atopic Dermatitis, Alopecia Areata, Hidradenitis Suppurativa, Vitiligo
Target PharmaSolutions, Inc.
Observational
15,000
Düren, Lübeck
2018-12-21
Active, closed
The RADIANCE II Pivotal Study: A Study of the ReCor Medical Paradise System in Stage II Hypertension
NCT03614260Hypertension, Vascular Diseases, Cardiovascular Diseases
ReCor Medical, Inc.
Not applicable
224
Erlangen, Homburg, Karlsruhe, Konstanz, Leipzig, Lübeck
2018-12-14
Active, closed
DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]
NCT03529110Breast Cancer
DrugsTrastuzumab emtansine·Trastuzumab deruxtecan
Daiichi Sankyo
Phase 3
524
Erlangen, Munich, Düsseldorf, Troisdorf, Bottrop, Lübeck
2018-08-09
Active, closed
Extended Access of Momelotinib in Adults With Myelofibrosis
NCT03441113Neoplasms, Post-polycythemia Vera Myelofibrosis (Post-PV MF), Primary Myelofibrosis (PMF), Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)
GlaxoSmithKline
Phase 2
237
Aachen, Cologne, Dresden, Halle, Leipzig, Lübeck, Mainz
2018-05-03
Recruiting
Clinical Cohort Study on the Endocrinology and Vaginal/Endometrial Microbiome of the Luteal Phase in Assisted Reproduction
NCT03507673Infertility
University of Luebeck
Observational
1,200
Saarbrücken, Lübeck, Düsseldorf, Kiel
2018-05-02
Active, closed
AHEAD: European Feasibility Study of the Cardiovalve Transfemoral Mitral Valve System
NCT03339115Mitral Regurgitation, Mitral Valve Disease
Cardiovalve Ltd.
Not applicable
30
Bonn, Cologne, Lübeck, Mainz, München
2018-04-23
Recruiting
Fosfomycin I.v. for Treatment of Severely Infected Patients
NCT02979951Bacterial Infections, Bone Diseases, Infectious, Osteomyelitis, Central Nervous System Bacterial Infections
Infectopharm Arzneimittel GmbH
Observational
1,000
Berlin, Braunschweig, Düsseldorf, Frankfurt, Hamburg, Jena, Kiel, Lübeck
2016-12
Active, closed
PORTEC-4a: Molecular Profile-based Versus Standard Adjuvant Radiotherapy in Endometrial Cancer
NCT03469674Endometrial Cancer Stage I, Endometrial Cancer Stage II
Leiden University Medical Center
Phase 3
550
Berlin, Düsseldorf, Essen, Heidelberg, Lübeck, Münich, Tübingen
2016-06-10
Active, closed
A Study of the ReCor Medical Paradise System in Clinical Hypertension
NCT02649426Hypertension, Vascular Diseases
ReCor Medical, Inc.
Not applicable
282
Düsseldorf, Erlangen, Freiburg im Breisgau, Homburg, Leipzig, Lübeck, Mainz
2016-03
Active, closed
A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC
NCT02489318Prostate Cancer
DrugApalutamide
Aragon Pharmaceuticals, Inc.
Phase 3
1,052
Bonn, Braunschweig, Eisleben Lutherstadt, Hamburg, Hanover, Leipzig, Lübeck, Nürtingen
2015-11-27
Recruiting
The German ADPKD Tolvaptan Treatment Registry
NCT02497521ADPKD (Autosomal Dominant Polycystic Kidney Disease)
University of Cologne
Observational
2,000
Müllheim, Würzburg, Hanover, Cologne, Nettetal, Leipzig, Lübeck, Berlin
2015-11
Recruiting
The GErman Italian Spanish Takotsubo (GEIST) Registry
NCT04361994Takotsubo Syndrome
Prof. Dr. med. Ingo Eitel
Observational
500
Lübeck
2015-04
Active, closed
A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer
NCT02246621Breast Cancer
DrugsAnastrozole·Abemaciclib·Letrozole
Eli Lilly and Company
Phase 3
493
Ludwigsburg, Ulm, München, Wiesbaden, Düsseldorf, Lübeck, Hamburg
2014-11-06
Active, closed
Biomarkerscreening in Cervical Cancer and Its Preinvasive Lesions
NCT02238990Evaluation of New Tissue Biomarkers for Cervical Cancer
University of Luebeck
Observational
100
Lübeck
2014-09
Active, closed
Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks
NCT02051218Metastatic Breast Cancer, Metastatic Prostate Cancer, Bone Metastases
DrugsReduced·Xgeva·Denosumab
Swiss Cancer Institute
Phase 3
1,380
Düsseldorf, Göttingen, Lübeck, Ulm
2014-07-16
Active, closed
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
NCT01874353Platinum Sensitive, BRCA Mutated, Relapsed Ovarian Cancer, Following Complete or Partial Response to Platinum Based Chemotherapy
DrugOlaparib
AstraZeneca
Phase 3
327
Berlin, Erlangen, Essen, Frankfurt, Hanover, Lübeck, München, Ravensburg
2013-09-03
Recruiting
Atypical Hemolytic-Uremic Syndrome (aHUS) Registry
NCT01522183Atypical Hemolytic-Uremic Syndrome
Alexion Pharmaceuticals, Inc.
Observational
3,000
Essen, Hanover, Heidelberg, Lübeck, Münster, Tübingen
2013-03-18
Recruiting
Pediatric Arm of DZL All Age Asthma Cohort
NCT02496468Asthma, Wheeze, Hypersensitivity, Endophenotype
LMU Klinikum
Observational
1,500
Cologne, Hanover, Lübeck, Marburg, Munich
2013-01
By invitation
Multicenter Prospective Cohort Study on Current Treatments of Legg-Calvé-Perthes Disease
NCT02040714Legg Calve Perthes Disease
Texas Scottish Rite Hospital for Children
Observational
1,500
Hamburg, Lübeck
2012-08
Recruiting
Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort
NCT01574053Huntington's Disease
CHDI Foundation, Inc.
Observational
35,000
Aachen, Berlin, Bochum, Dresden, Erlangen, Freiburg im Breisgau, Kassel, Lübeck
2012-07
Recruiting
Longitudinal Observational Study on the Course of Cystic Fibrosis Lung Disease in Patients Following Newborn Screening
NCT02270476Cystic Fibrosis Lung Disease
Heidelberg University
Observational
200
Heidelberg, Giessen, Hanover, Lübeck
2011-12
Recruiting
Improving Safety and Quality of Tracheal Intubation Practice in Pediatric ICUs
NCT02493478Failed or Difficult Intubation, Sequela, Intubation; Difficult, Intubation Complication
Children's Hospital of Philadelphia
Observational
150,000
Lübeck
2010-03
Rows per page Showing 1–225 of 225
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a German investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 30 September 2026. https://priyalifescience.com/clinical-trials-germany/city/l-beck

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Germany and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,051 studies in total at the last sync on 26 Sep 2026, 19:51 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 225 of those studies with a site in Lübeck.

How many clinical trials are recruiting in Lübeck?

120 of the 225 studies on this page are recruiting new participants as of the 26 Sep 2026, 19:51 UTC sync. A further 7 have not yet opened recruitment, 92 are active but closed to new participants, and 6 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Lübeck), 225 studies
PhaseStudiesRecruitingShare
Phase 3753333.3%
Not applicable462120.4%
Observational463520.4%
Phase 2301313.3%
Phase 1/211104.9%
Phase 1843.6%
Phase 2/3532.2%
Phase 4411.8%

Most active sponsors

Lead sponsors with the most studies (Lübeck)
Lead sponsorStudiesRecruiting
University Hospital Schleswig-Holstein104
University of Luebeck96
GlaxoSmithKline85
Novartis Pharmaceuticals81
AstraZeneca72
Abbott Medical Devices62
Prof. Dr. med. Ingo Eitel66
Bristol-Myers Squibb51
Eli Lilly and Company54
Merck Sharp & Dohme LLC53
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.